Benjamin N. Moskoff

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

J. Tuscano, M. Abedi, B. Jonas, 2021, Frontiers in Oncology.

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia

Tamer Othman, B. Jonas, Matthew E. Tenold, 2021, Expert review of hematology.

Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.

Naseem Esteghamat, J. Tuscano, C. Richman, 2021, Leukemia & lymphoma.

Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.

J. Tuscano, M. Abedi, B. Jonas, 2021, Clinical lymphoma, myeloma & leukemia.

Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.

Tamer Othman, B. Jonas, Matthew E. Tenold, 2021, Future Oncology.

Characterization of a multidisciplinary team’s role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia

Vera Pervitsky, B. Jonas, Ryan J. Beechinor, 2023, Supportive Care in Cancer.

Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.

P. Kaesberg, J. Tuscano, J. Welborn, 2022, Leukemia research.